Monthly Lecanemab Maintained Alzheimer’s Blood Biomarker Changes After 18 Months
TL;DR: A 2026 study in Alzheimer’s & Dementia: Translational Research & Clinical Interventions used lecanemab pharmacokinetic/pharmacodynamic modeling in early Alzheimer’s disease and found that blood biomarkers worsened after treatment stopped, while monthly…
Read article